AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19384953
Drug: Haplotype near
RxNorm normalized name: OCTINOXATE 3.5 mg in 1 mL / TITANIUM DIOXIDE 1.9 mg in 1 mL TOPICAL LIQUID [Revlon Nearly Naked Makeup]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haplotype near ASIP (rs4911414[T] and rs1015362[G])
Trial: 17465473
Drug: Hyoscine butyl
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butyl bromide injection
Trial: 11094012
Drug: 0.06 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg/kg rocuronium (adults)
Trial: 11094012
Drug: 0.12 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12 mg/kg rocuronium (children)
Trial: 11094012
Drug: 0.12, 0.18,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12, 0.18, or 0.24 mg/kg rocuronium (children)
Trial: 11094012
Drug: 0.06, 0.12,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06, 0.12, or 0.18 mg/kg rocuronium (adults)
Trial: 8354583
Drug: Ticlopidine 250
RxNorm normalized name: ticlopidine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 250 mg daily for 7 days
Trial: 3720527
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and d-amphetamine combination
Trial: 26239594
Drug: Partly supervised
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Partly supervised exercise programme (6 weeks supervised, followed by 6 weeks self-administered)
Trial: 26239594
Drug: Self-administered exercise
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered exercise programme (12 weeks)
Trial: 12657224
Drug: Clomipramine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine infusion (5mg in 5min) during head-up tilt test (Clom-HUT)
Trial: 12657224
Drug: Clomipramine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine infusion during tilt test
Trial: 9193243
Drug: Low-dose indomethacin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose indomethacin sodium for the prevention of intraventricular hemorrhage
Trial: 9193243
Drug: Chorioamnionitis, treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chorioamnionitis, treatment with surfactant, bronchopulmonary dysplasia, abnormal cranial US findings
Trial: 1586272
Drug: Standard-range lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-range lithium levels (0.8 to 1.0 mmol/L)
Trial: 1586272
Drug: Low-range lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-range lithium levels (0.4 to 0.6 mmol/L)
Trial: 1586272
Drug: Standard-range lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-range lithium therapy
Trial: 31098961
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine infusion (5 mg·kg−1)
Trial: 31098961
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo infusion (diphenhydramine 50 mg)
Trial: 27107066
Drug: All RSB
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All RSB groups (single-dose, repeated-dose, continuous infusion)
Trial: 25060946
Drug: Olmesartan medoxomil/amlodipine
RxNorm normalized name: olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide 40 mg-5 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/amlodipine 20/5 mg
Trial: 21282560
Drug: Olmesartan 40
RxNorm normalized name: HCTZ 25/OLMESARTAN 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 40 mg
Trial: 19149823
Drug: Rimonabant plus
RxNorm normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Rimonabant plus nicotine patch (n = 369)
Trial: 19149823
Drug: Rimonabant plus
RxNorm normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Rimonabant plus placebo patch (n = 366)
Trial: 19149823
Drug: Rimonabant plus
RxNorm normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Rimonabant plus nicotine patch
Trial: 15382410
Drug: Static magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Static magnetic therapy
Trial: 10071698
Drug: 5-mL injectate
RxNorm normalized name: von Willebrand factor
DrugBank: Von Willebrand factor human (DB13133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mL injectate
Trial: 10071698
Drug: 10-mL injectate
RxNorm normalized name: von Willebrand factor
DrugBank: Von Willebrand factor human (DB13133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mL injectate
Trial: 10071698
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 5-mL and 10-mL injectates
Trial: 7027894
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg metoprolol
Trial: 28580646
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg subcutaneously
Trial: 26376074
Drug: Stress dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress dose hydrocortisone (tapering 7-day course)
Trial: 26376074
Drug: Stress dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress dose hydrocortisone
Trial: 19623694
Drug: Posaconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d alone)
Trial: 19623694
Drug: Posaconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d) and Ritonavir (100 mg/d)
Trial: 19623694
Drug: Posaconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d)
Trial: 19623694
Drug: Posaconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d) and Efavirenz (400 mg/d)
Trial: 17277393
Drug: Targeted cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted cancer therapies (specifics not provided)
Trial: 15077933
Drug: Acupuncture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture with continued symptomatic medication (Group B)
Trial: 15077933
Drug: Symptomatic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic medication followed by acupuncture (Group C)
Trial: 11910689
Drug: Esmolol intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol intravenous (i.v.) at the dose of 150 micrograms.kg‐1
Trial: 2979286
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg b.d. for 4 weeks
Trial: 26252788
Drug: fedratinib 300
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fedratinib 300 mg once daily
Trial: 26252788
Drug: fedratinib 400
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fedratinib 400 mg once daily
Trial: 26252788
Drug: fedratinib 500
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fedratinib 500 mg once daily
Trial: 23337693
Drug: Rivaroxaban (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (dose not specified)
Trial: 21174055
Drug: Orofacial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orofacial therapy
Trial: 21174055
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no orofacial therapy)
Trial: 10553838
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 STIM: 24 patients received a single injection of 20 mL of a mixture of 2% lidocaine and 0.5% bupivacaine with 1:200,000 epinephrine.
Trial: 10553838
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 STIM: 26 patients received 10 mL of the same solution injected after stimulation of each sciatic nerve component.
Trial: 1677903
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg cetirizine administered orally
Trial: 1677903
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg cetirizine administered sublingually
Trial: 1677903
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg cetirizine administered orally or sublingually
Trial: 375686
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg imipramine
Trial: 26541814
Drug: Cariprazine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 0.75 mg/day
Trial: 25047139
Drug: Navitoclax 250
RxNorm normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax 250 mg
Trial: 25047139
Drug: Navitoclax 250
RxNorm normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax 250 mg with Rifampin 600 mg QD
Trial: 22951358
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion in combination with low dose eptifibatide infusion
Trial: 22951358
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion + eptifibatide
Trial: 11443167
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (40 g soy protein, 118 mg isoflavones)
Trial: 8825533
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg tablets on the night before and the morning of surgery, plus isotonic saline 0.3 ml iv before surgery ended.
Trial: 8825533
Drug: Droperidol 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.75 mg iv injected before the operation ended.
Trial: 3936140
Drug: Almitrine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine (200 mg/day for 9 days)
Trial: 19122308
Drug: Nocturnal home
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nocturnal home oxygen therapy (HOT)
Trial: 18218179
Drug: Exenatide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (5 mcg twice daily for 4 weeks, then 10 mcg thereafter)
Trial: 18218179
Drug: Insulin analogue
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin analogue therapy (glargine or biphasic insulin aspart)
Trial: 15721095
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and glycoprotein IIb/IIIa inhibition
Trial: 10789879
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg smoked cocaine
Trial: 1495889
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg adinazolam mesylate immediate-release (CT) tablets
Trial: 1495889
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg sustained-release (SR) tablets
Trial: 1495889
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg CT tablets every 8 hr
Trial: 1495889
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg SR tablets every 12 hr
Trial: 30105400
Drug: Daily teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily teriparatide injection (20-μg)
Trial: 30105400
Drug: Weekly teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly teriparatide injection (56.5-μg)
Trial: 27144848
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral cholera vaccine Shanchol
Trial: 25151225
Drug: Intravenous MVA85A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous MVA85A
Trial: 20131030
Drug: Yiqi Yangyin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Yangyin Decoction (YQYYD) with conventional therapy of Western medicine
Trial: 20131030
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy of Western medicine
Trial: 17542349
Drug: Sarizotan 5-25
RxNorm normalized name: Sarizotan
DrugBank: Sarizotan (DB06454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarizotan 5-25 mg single doses
Trial: 17542349
Drug: Sarizotan 10
RxNorm normalized name: Sarizotan
DrugBank: Sarizotan (DB06454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarizotan 10 and 20 mg b.i.d. multiple doses
Trial: 17542349
Drug: Sarizotan 5
RxNorm normalized name: Sarizotan
DrugBank: Sarizotan (DB06454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarizotan 5 mg b.i.d. multiple doses
Trial: 15007784
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (300 mg/d, with initial run-in of 150 mg/d for the first three days)
Trial: 11727145
Drug: Clonidine 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 4.5 mg/kg
Trial: 8387697
Drug: Combined radiotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined radiotherapy with fast neutrons (average dose 569 cGy) and photons (average dose 36.86 Gy)
Trial: 8387697
Drug: Boost therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boost therapy or mixed beam therapy with localized fast neutron field
Trial: 3308650
Drug: TDB 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDB 120 mg quid
Trial: 3308650
Drug: cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 400 mg tid
Trial: 3308650
Drug: cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 400 mg with meals plus 800 mg at bedtime
Trial: 25776457
Drug: GP IIb/IIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP IIb/IIIa receptor inhibitors
Trial: 18159027
Drug: Indomethacin tablet
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin tablet
Trial: 16335913
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (2 mg) and dienogest (2 mg)
Trial: 9797910
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplementation (1 g calcium carbonate and 14 micrograms vitamin D3)
Trial: 8586825
Drug: Diuretics (altizide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (altizide and spironolactone)
Trial: 9767545
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist (verapamil)
Trial: 1116382
Drug: Rimiterol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimiterol (0.5 mg)
Trial: 3899082
Drug: Salbutamol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.2 mg)
Trial: 29262813
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg (ARB)
Trial: 29262813
Drug: ARB +
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB + Hydrochlorothiazide 25 mg (HCT)
Trial: 29262813
Drug: ACE inhibition
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibition (Lisinopril 40 mg/day)
Trial: 29262813
Drug: Dual RAASi
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual RAASi (Lisinopril 40 mg/day + Valsartan 320 mg/day)
Trial: 24795092
Drug: Intravenous doripenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous doripenem (DRPM) 0.5 g three times daily
Trial: 24795092
Drug: Imipenem/cilastatin (IPM/CS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (IPM/CS) 0.5 g three times daily
Trial: 24795092
Drug: Intravenous doripenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous doripenem (DRPM)
Trial: 10771863
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prolonged latency and prolonged interval
Trial: 28571996
Drug: Etanercept (TNF-alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (TNF-alpha inhibitor)
Trial: 16959828
Drug: GFR <40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFR <40 ml/min
Trial: 15488354
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg micronised 17 beta‐oestradiol/5 mg dydrogesterone (E/D)
Trial: 15488354
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine oestrogens/5 mg medroxyprogesterone acetate (CEE/MPA)
Trial: 7826792
Drug: Extradural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural sufentanil (initial bolus of 50 micrograms followed by 10 micrograms, self-administered using PCA, mean 275 micrograms)
Trial: 7826792
Drug: Extradural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural sufentanil (initial bolus of 50 micrograms followed by 10 micrograms, administered by a nurse on request, mean 144 micrograms)
Trial: 7826792
Drug: i.m. morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. morphine (mean 52 mg, range 30‐80 mg, administered on request)
Trial: 28754119
Drug: YY-312 (2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YY-312 (2400 mg daily, containing 1800 mg of active herbal extract and 600 mg of cyclodextrin)
Trial: 26618455
Drug: VYC‐20L (hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VYC‐20L (hyaluronic acid gel)
Trial: 20863604
Drug: Natural childbirth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural childbirth preparation with psychoprophylaxis
Trial: 19485825
Drug: Acetaminophen 500
RxNorm normalized name: acetaminophen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500 mg with caffeine 30 mg
Trial: 14686080
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment package targeting headache symptoms and associated posttraumatic stress symptoms
Trial: 14686080
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment package
Trial: 12549975
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (2 g)
Trial: 12549975
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C (4 g/day for 4 weeks)
Trial: 11024416
Drug: Topical beta-blockers
RxNorm normalized name: Beta-HC Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical beta-blockers
Trial: 11024416
Drug: Close observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Close observation (no topical medication)
Trial: 6362832
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with nonviable Mycobacterium smegmatis, given monthly by subcutaneous injection in four sites.
Trial: 6171572
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified treatment).
Trial: 3543092
Drug: Diltiazem (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (90 to 360 mg)
Trial: 3543092
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 to 120 mg)
Trial: 3543092
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diltiazem and nifedipine
Trial: 31811562
Drug: Apheresis therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apheresis therapy (twice per month for 12 months)
Trial: 31811562
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no apheresis treatment)
Trial: 23249916
Drug: Extended infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended infant nevirapine (NVP) administration
Trial: 23249916
Drug: Maternal antiretroviral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal antiretroviral treatment regimen (including NVP or efavirenz)